Transfemoral J-Valve device improves symptoms in severe aortic regurgitation patients

Patients experienced sustained improvements in symptoms and health status. At one year, their New York Heart Association functional class improved in 72.7% of patients, with 95.5% in Class I or II. Reverse left ventricular remodeling was evident at 30 days and sustained through one year. Continued follow-up through five years is planned, and more definitive evidence is expected from the larger ongoing JOURNEY trial.

The J-Valve trial was funded by JC Medical, Inc., an affiliate of Edwards Lifesciences LLC.

Source:

Society for Cardiovascular Angiography and Interventions

Journal reference: